Symposium 16: Pharmacological treatment (statins and combination drugs)
DOI:
https://doi.org/10.47196/diab.v54i3Sup.331Keywords:
pharmacological treatment, diabetesAbstract
Symposium 16: Diagnosis and management of diabetic dyslipidemia
Pharmacological treatment (statins and combination drugs)
Statins constitute the undisputed pharmacological treatment of diabetic dyslipidemia.
The guidelines recommend using moderate to high-intensity statins as the first line of treatment, since they reduce cardiovascular risk beyond the LDL-c level. However, even receiving maximum doses of these drugs, not everyone achieves the established LDL-c goals. Many patients will require the addition of non-statin lipid-lowering agents as combination treatment.
References
- Cannon CP, et al. IMPROVE IT. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.
- Robinson JG, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16): 1489–99.
- Sabatine MS, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16): 1500–9.
- Lloyd-Jones DM, et al. A report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785–822.
- Garber AJ, et al. Consensus Statement by The American Association of Clinical Endocrinologists and American College of Endocrinology. Type 2 Diabetes management algorithm- 2020 executive summary.
- American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2020.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
